GLOBUS MEDICAL INC
No SEC Form 4 filings for $GMED in the last 30 days.
Globus Medical (NYSE:GMED) reported Q2 CY2026 revenue of $789.6 million, up 5.9% year on year and 0.9% above analysts’ estimates, according to the company. Non-GAAP EPS was $1.34, 21.9% above consensus. The company guided full-year revenue to about $3.2 billion, near estimates.
GLOBUS MEDICAL INC (GMED) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 gmed-q22026ex991.htm EX-99.1 Document Exhibit 99.1 Globus Medical Reports Second Quarter 2026 Results AUDUBON, PA., August 6, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quar
Globus Medical (NYSE: GMED) is set to report Q2 earnings Thursday. The company previously beat revenue expectations with $759.9 million in Q1, up 27% year on year. For Q2, analysts expect revenue growth of 5% year on year. GMED has an average analyst price target of $103.92 versus a $81.39 share price.
Over the past 7 days, alphai's AI scored 3 news stories mentioning GMED (GLOBUS MEDICAL INC). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent GMED coverage spans earnings, financial news and sector analysis.
Beat on revenue and adjusted EPS with margin strength, while full-year revenue guidance is roughly in line.
Guidance update and Q2 margin/EPS trends create a near-term repricing setup for GMED, with focus on non-GAAP EPS durability and revenue growth quality.
This is a pre-earnings setup piece, not a new earnings print. The actionable angle is positioning around whether GMED can beat the 5% YoY revenue expectation and maintain guidance momentum.
GMED is being repriced on the same hospital volume demand signal affecting the broader device complex.
Globus Medical is referenced only as an adviser; the article does not disclose a new Globus event.
alphai scores every news story that mentions GMED with an AI model for sentiment and relevance, and aggregates insider trades from GLOBUS MEDICAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Globus Medical (NYSE:GMED) reported Q2 CY2026 revenue of $789.6 million, up 5.9% year on year and 0.9% above analysts’ estimates, according to the company. Non-GAAP EPS was $1.34, 21.9% above consensus. The company guided full-year revenue to about $3.2 billion, near estimates.
4 min readGLOBUS MEDICAL INC (GMED) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 gmed-q22026ex991.htm EX-99.1 Document Exhibit 99.1 Globus Medical Reports Second Quarter 2026 Results AUDUBON, PA., August 6, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quar
6 min readGlobus Medical (NYSE: GMED) is set to report Q2 earnings Thursday. The company previously beat revenue expectations with $759.9 million in Q1, up 27% year on year. For Q2, analysts expect revenue growth of 5% year on year. GMED has an average analyst price target of $103.92 versus a $81.39 share price.
4 min readMedical device stocks fell after HCA Healthcare reported preliminary Q2 results with weaker-than-expected surgical volumes. GE Healthcare, Intuitive Surgical, Stryker, Globus Medical and Medtronic dropped 4.7% to 7%, with other peers also down. Wells Fargo analyst Larry Biegelsen expects further declines as demand concerns are likely to be discussed on earnings calls.
3 min readThe article describes a shift toward handheld and miniaturized surgical navigation rather than full-size spine robots. It cites OrthAlign’s June 3 FDA clearance for Lantern ASC and early joint cases using Smith+Nephew’s CORI XT. In spine, it highlights Bolt Nav pedicle-screw guidance and Apple Vision Pro paired with Stryker Q navigation, plus Stryker Mako 4.0 spine robot cases, arguing economics favor lightweight navigation.
7 min readDavidar David D sold 25,000 shares of GLOBUS MEDICAL INC (GMED) at $80.76 ($2.02M total) on 2026-06-05.
1 min readWells Fargo cut its price target on Globus Medical (GMED) to $103 from $104 while keeping an Overweight rating, citing the company’s fiscal Q1 2026 results that beat consensus on sales and EPS, according to the report. Globus Medical reported worldwide net sales of $759.9M (+27%); base business net sales were $677.2M (+13.2%).
2 min readWhen a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
3 min readPARR, AU, GMED, ALNT and SNDK emerge as top picks after posting gains, rising estimates and sustained relative price outperformance.
4 min readGlobus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
2 min read
